Erasca (ERAS) Total Current Liabilities (2020 - 2026)
Erasca's (ERAS) quarterly Total Current Liabilities came in at $26.7 million in Q1 2026, up 4.68% YoY from $25.5 million in Q1 2025, and down 6.48% on a QoQ basis from $28.5 million in Q4 2025.
Erasca (ERAS) Total Current Liabilities (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Total Current Liabilities data on file, last reported at $26.7 million in Q1 2026.
- Quarterly Total Current Liabilities rose 4.68% year-over-year to $26.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.7 million (up 4.68% YoY) and the FY2025 annual result came in at $28.5 million, down 9.19% from the prior year.
- Total Current Liabilities eased to $26.7 million in Q1 2026, from $28.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $48.7 million in Q4 2022 to a low of $21.4 million in Q1 2022.
- A 5-year average of $28.0 million and a median of $26.7 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 85.68% — and 2023, when it plunged 46.28%.
- Tracing ERAS's Total Current Liabilities over 5 years: stood at $48.7 million in 2022, then slumped by 46.28% to $26.2 million in 2023, then advanced by 20.03% to $31.4 million in 2024, then retreated by 9.19% to $28.5 million in 2025, then fell by 6.48% to $26.7 million in 2026.
- The last three Total Current Liabilities figures came in at $26.7 million (Q1 2026), $28.5 million (Q4 2025), and $28.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 33.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.57 Mn |
| Mar 31, 2026 | 26.66 Mn |
| Dec 31, 2025 | 28.51 Mn |
| Sep 30, 2025 | 28.71 Mn |
| Jun 30, 2025 | 28.15 Mn |
| Mar 31, 2025 | 25.47 Mn |
| Dec 31, 2024 | 31.40 Mn |
| Sep 30, 2024 | 30.03 Mn |
| Jun 30, 2024 | 24.89 Mn |
| Mar 31, 2024 | 30.24 Mn |
| Dec 31, 2023 | 26.16 Mn |
| Sep 30, 2023 | 26.73 Mn |
| Jun 30, 2023 | 23.29 Mn |
| Mar 31, 2023 | 25.52 Mn |
| Dec 31, 2022 | 48.69 Mn |
| Sep 30, 2022 | 27.68 Mn |
| Jun 30, 2022 | 22.32 Mn |
| Mar 31, 2022 | 21.39 Mn |
| Dec 31, 2021 | 26.22 Mn |
| Sep 30, 2021 | 19.59 Mn |